The development of new drugs is a costly and time-consuming process, often spanning over a decade. Drug repurposing has emerged as a promising alternative, leveraging existing compounds to identify novel therapeutic uses. In this context, DRIVE (Data-dRiven platform for dIsease Visualization and Drug rEpurposing) is a platform designed to integrate and exploit heterogeneous biomedical data to support hypothesis generation in drug repurposing. Developed at the Medical Data Analytics Laboratory (MEDAL) of Universidad Politécnica de Madrid, DRIVE combines disease-centered network visualizations and six complementary computational methods, ranging from data-driven-based approaches to graph neural network models. The platform is powered by data from DISNET and integrates phenotypic, molecular, and pharmacological layers of knowledge. Users can interactively explore disease mechanisms, visualize multi-layer disease networks, and obtain ranked repurposing candidates through a web interface. This poster presents the platform architecture, discusses the methodologies implemented, and illustrates the capabilities of DRIVE through representative use cases.

Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by complex, cell-type-specific molecular alterations. This study integrates single-cell RNA sequencing (scRNA-seq) with network-based methodologies to decode transcriptional changes across major brain cell types in AD. Using scRNA-seq data from 432,555 single cells, we constructed ProteinProtein Interaction (PPI) networks specific to each cell type and assessed the differential expression of genes in diseased conditions. Our findings reveal that glutamatergic neurons and inhibitory interneurons exhibit the highest transcriptional dysregulation, while pericytes and endothelial cells show limited changes. The analysis identified significant enrichment of Differentially Expressed Genes (DEGs) within the AD protein module. Network analysis highlights highly connected proteins such as HSPB1, which is implicated in proteostasis, and CXCR4, which is involved in neuroinflammation. Our results underscore the importance of cell-type-specific approaches in AD research, demonstrating that neurons experience more extensive dysregulation, while vascularassociated cells play key roles in maintaining Blood-Brain Barrier (BBB) integrity. These insights emphasize the necessity of tailored therapeutic strategies addressing the heterogeneous molecular landscape of AD.

Rare diseases are a collection of unusual pathologies that afflict millions of individuals globally. However, the creation of treatments for these conditions is frequently limited due to the high expenses and lack of profitability associated with drug development. Orphan drugs, which are medications specifically designed for rare diseases, have played a pivotal role in treating these diseases over the past several years. Nevertheless, their creation remains challenging, and many rare diseases lack approved therapies. Therefore, drug repurposing has emerged as a viable strategy for identifying potential new treatments for these pathologies. A technique that consists in using existing drugs to treat a new disease different from the one that they were developed. This approach can significantly reduce the time and cost of drug development while increasing the likelihood of success. In this paper, we examined the temporal progression of orphan drugs since their introduction and assess the impact of drug repositioning on treatments for rare diseases. Additionally, we aim to identify biological patterns that may be unique to rare diseases treated with repurposed orphan drugs. To this end, we analyzed various biological components associated with these diseases, categorized linked diseases, and obtained the type of orphan drug associated with them. Lastly, we evaluated the phenotypic similarity between diseases treated with an orphan drug through repurposing. Through these findings, we have gained insight into the evolution of orphan drug development in recent years and identified specific patterns that characterize rare diseases associated with them.

Drug repurposing, the process of finding new uses for existing drugs, has gained considerable attention due to its potential to reduce the time and costs associated with drug development. Personalized drug repurposing, in which drugs are selected based on the characteristics of individual patients, is an emerging approach that holds promise for improving clinical outcomes. In this context, exploring disease-drug pairs in already conducted clinical trials can provide valuable insights to identify promising patient populations for further study that may lead to personalized drug repositioning. Our analysis aims to shed a light into clinical outcomes by selecting the most appropriate repurposed drug based on clinical trials patient groups' characteristics, such as age and gender. It also gives information about the state of the clinical trials studying these disease-drug pairs, gathering information about the study type, phase and statistical method used to calculate the p-value of the chosen outcome measurement, among others. Overall, this study highlights the importance of using existing knowledge as an initial framework to facilitate further research, particularly in providing patient-specific information. Furthermore, it underlines the importance of building on previous research to facilitate a comprehensive understanding of the research topic, which can eventually improve patient outcomes.